Epitopea Adds Cancer Immunotherapy Expert to Advisory Board — Epitopea Ltd.

Event summary

Epitopea appointed Lisa Butterfield to its Scientific Advisory Board (SAB) on April 13, 2026.
Butterfield previously held leadership roles at Merck, the University of Pittsburgh, and the Parker Institute for Cancer Immunotherapy.
She served as the first female President of the Society for Immunotherapy of Cancer (SITC) and chaired the FDA’s Cell, Tissue and Gene Therapy Advisory Committee.
Butterfield’s expertise focuses on cancer vaccines, immune profiling, biomarker development, and cellular therapies for solid tumors.
Epitopea is developing CryptiVax™-1001, an mRNA therapeutic vaccine for high-grade serous ovarian cancer, leveraging its Cryptigen™ TSA platform.

The big picture

The appointment of a high-profile figure like Lisa Butterfield signals Epitopea’s ambition to accelerate its pipeline and compete in the increasingly crowded cancer immunotherapy space. Her experience navigating both academic and industry settings suggests a focus on translational research and rapid clinical advancement. The company’s reliance on a novel immunopeptidomics and genomics platform to identify tumor-specific antigens represents a potentially disruptive approach, but its success hinges on demonstrating broad applicability and clinical efficacy.

What we're watching

Clinical Progress: The speed at which Epitopea can translate Butterfield’s insights into accelerating the clinical development and regulatory approval of CryptiVax™-1001 will be a key indicator of the SAB’s impact.
Platform Validation: Whether Butterfield’s expertise validates the core Cryptigen™ TSA discovery platform and its ability to identify broadly applicable antigens across various solid tumor types remains to be seen.
Competitive Landscape: How Epitopea’s off-the-shelf RNA-based approach stacks up against other cancer immunotherapy strategies, particularly those leveraging personalized or cellular therapies, will determine its long-term market positioning.